Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs
AssigneeShanghai Zheye Biotechnology Co. Ltd.
InventorsFengtian Du, Haibo Wang, Qiang Zhang
Life of this patent
Estimating the term…
Abstract
Provided are a compound containing an aromatic group as well as a stereoisomer, a tautomer or a pharmaceutically acceptable salt of the compound. Further provided is a method related to preparation and use of the compound. A pharmaceutical composition containing the compound and a related cancer treatment method are involved. The disclosed aromatic group-containing compound has remarkable inhibitory activity on protein, and has a wild application prospect in the field of tumor treatment.
Claims39
A compound of formula (A), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof,
- wherein, J is nitrogen atom, or CH;
- Ring B is aryl, heteroaryl;
- C is the following group:
- wherein, carbon atom at “3” position is connected with Ring A, carbon atom at “7” position is connected with Ring B;
- U is nitrogen atom or CRU, wherein RU is hydrogen or deuterium;
- M is oxygen atom, or sulfur atom;
- X is nitrogen atom or CR1, Y is nitrogen atom or CR2, Z is nitrogen atom or CR3;
- Ra, Rb are independently hydrogen, deuterium, halogen;
- Rd, Re are independently hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, hydroxyl, amino, sulfonyl, sulfonamido, amido, alkenyl, alkynyl;
- Ring A is nitrogen-containing heterocyclyl;
- R1, R2, R3, R15a, R15b, R15c, R17a, R17b, R17c, R17d, R17e, R17f, R17g, R17h are independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, deuterated alkyl, haloalkyl, alkenyl, alkynyl;
- Q is —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —C(18O)—;
- L is alkynyl, alkenyl, haloalkyl.
A compound of formula (II), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof,
- wherein, X is nitrogen atom or CR4, Y is nitrogen atom or CR5;
- U is nitrogen atom or CRU, wherein RU is hydrogen or deuterium;
- R1, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R3a, R3b, R3c, R4, R5, R12, R13, R14, R15a, R15b, R15c are independently selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl;
- R6a, R6b, R6c, R6d, R6e, R6f, R6g, R6h are independently selected from the group consisting of hydrogen, deuterium, methyl, methyl-d3;
- R7 is fluorine, chlorine;
- R8, R9, R10, R11 are independently selected from the group consisting of hydrogen, deuterium, fluorine;
- structural fragment
- is selected from the following structures:
- structural fragment
- is selected from the following structures:
- structural fragment
- is selected from the following structures:
- structural fragment
- is selected from the following structures:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound of formula (VI), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof,
- wherein, axial chiral stereoscopic configuration formed by connection of nitrogen atom at position 1 of Ring E and carbon atom at position 1′ of Ring F is optically pure;
- X is nitrogen atom or CR4, Y is nitrogen atom or CR5;
- R1, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R4, R5, R12, R13, R14, R15a, R15b, R15c are independently selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, halogen;
- R6a, R6b, R6c, R6d, R6e, R6f, R6g, R6h are independently selected from the group consisting of hydrogen, deuterium, methyl, methyl-d3;
- R7 is fluorine, chlorine;
- R8, R9, R10, R11 are independently selected from the group consisting of hydrogen, deuterium, fluorine;
- R17 is hydrogen, alkyl, deuterated alkyl, haloalkyl, methyl, ethyl, propyl, cyclopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated cyclopropyl.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.